DSCSA Trading Partner Verification: A Practical Guide for Wholesale Distributors

DSCSA Trading Partner Verification: A Practical Guide for Wholesale Distributors

Wholesale drug distributors operating under the Drug Supply Chain Security Act (DSCSA) may only transact with verified Authorized Trading Partners (ATPs). As of August 27, 2025, FDA enforcement discretion for wholesale distributors expired, requiring full compliance with ATP verification requirements under Section 582 of the Federal Food, Drug, and Cosmetic Act. This article details the statutory basis for ATP verification, the verification methods available to wholesale distributors, and the documentation requirements for maintaining compliant trading partner relationships.

Background and Regulatory Context

The Drug Supply Chain Security Act was enacted November 27, 2013, as Title II of the Drug Quality and Security Act (Pub. L. 113-54). DSCSA established national requirements for tracing prescription drugs through the U.S. pharmaceutical supply chain and created the legal framework for Authorized Trading Partner verification.

DSCSA regulates five entity types:

• Manufacturers and repackagers — Subject to FDA registration under Section 510 of the FD&C Act
• Wholesale distributors — Subject to state licensure requirements under Section 582(a)(6)
• Third-party logistics providers (3PLs) — Subject to state or federal licensure under Section 583
• Dispensers (pharmacies, hospitals) — Subject to state pharmacy licensure

The Act defines "authorized" differently for each entity type. Section 581(2) of the FD&C Act defines an authorized manufacturer as one with valid FDA registration. Section 581(19) defines an authorized wholesale distributor as one with valid state licensure. Section 581(17) and 581(6) extend similar licensure-based definitions to 3PLs and dispensers.

Enforcement Timeline

Enhanced DSCSA requirements—including package-level serialized data exchange and electronic interoperability—activated November 27, 2023. FDA announced a one-year stabilization period in August 2023 to allow supply chain participants to establish connections and resolve technical issues. When the stabilization period ended November 27, 2024, FDA issued sector-phased enforcement discretion periods in October 2024:

• Manufacturers and repackagers: Exemption expired May 27, 2025
• Wholesale distributors: Exemption expired August 27, 2025
• Dispensers with 26+ full-time employees: Exemption expired November 27, 2025
• Small dispensers (25 or fewer employees): Exemption expires November 27, 2026

Wholesale distributors are now under full enforcement for all DSCSA requirements, including ATP verification obligations.

Key Requirements

Authorized Trading Partner Verification

Section 582(b)(1)(A)(i) of the FD&C Act requires wholesale distributors to "not accept ownership of a product unless the previous owner prior to, or at the time of, the transaction provides the transaction history, transaction information, and a transaction statement." Section 582(d)(2) prohibits wholesale distributors from providing a covered drug product to an entity unless that entity is an authorized trading partner.

ATP status is determined by entity type:

Wholesale distributors must verify ATP status before the initial transaction with a trading partner and maintain verification records for a minimum of six years under Section 582(d)(1)(D).

Documentation Requirements

Wholesale distributors must maintain the following records for each trading partner:

For upstream suppliers (manufacturers, repackagers, other wholesalers, 3PLs):

• Copy of valid state license or FDA registration certificate
• Date of verification
• Source consulted for verification (state board website, FDA database, NABP Pulse)
• Verification performed by (name/title)

For downstream customers (dispensers, other wholesalers, 3PLs):

• Copy of valid state license
• Date of verification
• Periodic reverification records demonstrating ongoing license validity

All ATP verification records must be retained for six years from the date of the transaction or verification, per Section 582(d)(1)(D).

Annual Reporting to FDA

Section 583 of the FD&C Act requires wholesale distributors and 3PLs to report annually to FDA via CDER Direct. The annual report must include:

• Facility contact information and identifying details
• State licensure information for all jurisdictions where the entity operates
• Any disciplinary actions taken by state or federal regulatory authorities against the entity

Failure to submit the annual report may result in enforcement action and could affect the entity's ATP status.

Compliance Steps

Step 1: Establish Written Verification Procedures

Develop written policies and procedures documenting:

• ATP verification methods for each trading partner type
• Verification frequency (initial and ongoing reverification schedule)
• Documentation standards (what records are collected and how they are stored)
• Responsible personnel for performing verifications
• Escalation procedures for expired or invalid licenses

Written policies must reflect actual practice. National Association of Boards of Pharmacy (NABP) inspection findings indicate that many wholesale distributors maintain ATP verification policies but fail to execute routine reverification. Document every verification attempt, including null results.

Step 2: Verify Trading Partner Licenses Using Primary Sources

Use the following verification methods based on trading partner type:

For manufacturers and repackagers:

• Verify FDA registration via FDA's Electronic Drug Registration and Listing System (eDRLS) at https://www.fda.gov/drugs/drug-approvals-and-databases/drug-establishments-current-registration-site
• Confirm the registration includes the specific facility transacting with your organization
• Note the registration expiration date (FDA registrations renew annually between October 1 and December 31)

For wholesale distributors and 3PLs:

• Verify state licensure via the appropriate state board of pharmacy website
• Confirm the license covers wholesale distribution (not just retail pharmacy)
• Check license expiration date and any disciplinary actions on record
• For entities operating in multiple states, verify licensure in each relevant jurisdiction

For dispensers:

• Verify state pharmacy licensure via state board of pharmacy records
• Confirm the license is active and covers the dispensing location transacting with your organization

Step 3: Use NABP Pulse for Centralized Verification

The National Association of Boards of Pharmacy operates the Pulse platform, which provides:

• ATP status directories aggregating state license and FDA registration data
• Product identifier verification (GTIN, serial number, lot, expiration)
• Trace request functionality for suspect or illegitimate products
• Regulatory communication channels

Pulse is free for trading partners to maintain profile information. Some advanced features require paid subscriptions. Access Pulse at https://nabp.pharmacy/programs/accreditations-inspections/pulse/.

Step 4: Document Verification and Establish Reverification Schedule

For each trading partner:

1. Collect and file a copy of the current license or registration certificate
2. Record the verification date, source consulted, and verifying individual
3. Set a calendar reminder for reverification before the license expiration date
4. Establish a routine reverification schedule (quarterly or semi-annually recommended) independent of expiration dates

Do not rely on initial verification alone. State boards revoke or suspend licenses for compliance violations. FDA registrations lapse if not renewed. Routine reverification detects authorization lapses before they result in non-compliant transactions.

Step 5: Handle Discovered Authorization Lapses

If reverification reveals an expired or suspended license:

1. Immediately cease transactions with the affected trading partner
2. Notify the trading partner in writing of the authorization lapse
3. Quarantine any products received from the affected partner during the lapsed period
4. Document the lapse, notification, and quarantine actions
5. Request updated license documentation before resuming transactions
6. Reverify ATP status after the trading partner resolves the lapse

If the lapse involves a downstream customer, confirm the customer has resolved the issue with their state board before resuming shipments.

Step 6: Maintain Records for Six Years

Section 582(d)(1)(D) requires wholesale distributors to maintain ATP verification records for six years. Implement a document retention system that:

• Archives verification records by trading partner and date
• Tracks document expiration and destruction dates
• Allows retrieval during FDA or state board inspections
• Supports audit trail documentation showing verification frequency and compliance with written policies

Electronic record systems are permissible under DSCSA. Ensure electronic systems comply with 21 CFR Part 11 if used for regulatory records subject to FDA inspection.

ColdChainCheck Insights

DSCSA Compliance Indicators in Our Dataset

ColdChainCheck tracks 1,275 wholesale drug distributors, third-party logistics providers, and specialty distributors across 51 U.S. jurisdictions. The following table presents ATP verification signals available in the directory as of February 2026:

What the Data Reveals

Near-universal FDA registration (97%) suggests most entities in the directory operate as manufacturers, repackagers, or maintain dual manufacturer-wholesaler operations requiring Section 510 registration. The low NABP accreditation rate (5%) reflects the voluntary nature of NABP's Verified-Accredited Wholesale Distributors (VAWD) program — state licensure, not NABP accreditation, determines ATP status for wholesale distributors. The 6% recall rate (73 entities) indicates that a non-trivial portion of otherwise-licensed entities have experienced product quality or distribution control failures documented in FDA's enforcement database. Only 24% of entities score in the Good or Excellent tiers, reflecting incomplete public data availability across state licensing boards rather than widespread non-compliance — most entities hold required licenses but those records are not uniformly accessible via standardized data feeds. See ColdChainCheck's scoring methodology for details on how compliance signals are weighted.

How to Use ColdChainCheck for Trading Partner Verification

• Pre-qualification screening: Before initiating contact with a potential trading partner, check the entity's compliance score and license coverage in ColdChainCheck's directory. An entity scoring below 40 may indicate incomplete public records requiring additional manual verification effort.
• Recall history cross-check: ColdChainCheck surfaces FDA recall data linked to specific entities. During trading partner qualification, verify whether a prospective partner has recalls on record and request documentation of corrective actions taken.
• State license cross-reference: The directory aggregates state license data across 51 jurisdictions. Use it to confirm which states a multi-jurisdiction distributor is licensed in, then verify expiration dates directly with the relevant state board of pharmacy.
• Ongoing monitoring support: Revisit trading partner profiles quarterly to detect changes in compliance posture. ColdChainCheck updates license status, recall records, and FDA registration data as new information becomes available from source agencies.

Resources

• FDA Drug Supply Chain Security Act (DSCSA) — Official FDA DSCSA resource center
• FDA Guidance: Identifying Trading Partners Under DSCSA — FDA guidance on ATP verification
• NABP Pulse Platform — Centralized ATP verification and product tracing system
• FDA Drug Establishment Registration — eDRLS database for manufacturer/repackager verification
• Healthcare Distribution Alliance DSCSA Resources — Industry association guidance on DSCSA compliance
• GS1 US DSCSA Standards — EPCIS implementation standards for interoperable data exchange
• Text of the Drug Supply Chain Security Act (FD&C Act Sections 581-585) — Full statutory text
• FDA CDER Direct — Annual reporting portal for wholesale distributors and 3PLs

Disclaimer: This article provides informational content on DSCSA trading partner verification requirements and is not legal or regulatory advice. Wholesale distributors should consult qualified regulatory counsel and their state board of pharmacy to ensure compliance with all applicable federal and state requirements.

Update: DSCSA Enforcement Requirements for Wholesale Distributors

February 20, 2026

DSCSA Enforcement Phase: Critical Preparedness Requirements for Distributors and Trading Partners

The FDA began active enforcement of the Drug Supply Chain Security Act (DSCSA) on November 27, 2024, ending a grace period that allowed wholesale drug distributors to operate without full system interoperability. Distributors must now validate trading partner credentials through electronic systems, implement product-level serialization protocols, and maintain comprehensive transaction data for all prescription drug movements.

Regulatory Background

The DSCSA (Public Law 113-54) established national standards for tracing prescription drugs through the U.S. supply chain. Title II of the Act outlines requirements for wholesale distributors, including licensing standards under Section 582 and transaction information, transaction history, and transaction statement (TI/TH/TS) requirements under Section 582(c)(1).

FDA's final guidance "Product Identifier Requirements Under the Drug Supply Chain Security Act — Compliance Policy" (issued November 2024) defines the agency's enforcement posture. Distributors must verify product identifiers using the standardized numerical identifier (SNI) established in 21 CFR 1271.370, which requires a unique identifier at the saleable unit level.

The National Association of Boards of Pharmacy (NABP) administers the Verified-Accredited Wholesale Distributors (VAWD) program, the industry standard for third-party accreditation. While VAWD accreditation is voluntary, it signals compliance with NABP Model Rules for the Licensure of Wholesale Distributors — which 47 states have incorporated into their licensing requirements.

Key Enforcement Requirements

Trading Partner Verification: Distributors must maintain a current list of authorized trading partners and verify each partner holds valid state licenses before conducting transactions. Under 21 CFR 582(c)(4), verification must occur through direct confirmation with the relevant state board of pharmacy or through an FDA-approved third-party database. Self-attestation is not sufficient.

Transaction Documentation: Every product transfer requires complete TI/TH/TS documentation. Transaction Information must include the product identifier, transaction date, shipment information, and source/destination details. Transaction History must provide a complete pedigree from manufacturer to current holder. Transaction Statements must affirm the product was received from an authorized trading partner and list all prior transactions.

Product Identifier Verification: Distributors must verify the product identifier on each package or homogenous case against data provided by the previous owner. This applies to saleable units — not just shipper cases. FDA requires verification within one business day of receipt and before further distribution.

Data System Interoperability: Systems must support Electronic Product Code Information Services (EPCIS) format for data exchange and integrate with Verification Router Service (VRS) infrastructure for suspect product inquiries. Distributors unable to exchange serialized data electronically face operational restrictions under the November 2024 enforcement guidance.

Quarantine and Investigation Protocols: Receipt of an illegitimate product notification triggers mandatory quarantine under 21 CFR 582(d)(4). Distributors have 24 hours to quarantine affected inventory, notify trading partners in the distribution chain, and submit a report to FDA through the Drug Supply Chain Security Act Notification Portal.

Operational Impact for Distributors

State licensing coverage determines transaction capacity. Distributors licensed in fewer than 30 states face geographic limitations on sourcing and distribution networks. ColdChainCheck data shows 62% of tracked entities hold licenses in fewer than 10 states, creating bottlenecks in multi-state distribution models.

NABP accreditation affects trading partner acceptance. Large health systems and specialty pharmacy networks increasingly require VAWD accreditation as a vendor qualification prerequisite. Only 4.9% of tracked distributors hold current NABP accreditation, creating competitive pressure for entities without third-party validation.

FDA registration alone does not satisfy DSCSA requirements. All 1,234 FDA-registered entities in the ColdChainCheck directory must also maintain state licenses in each jurisdiction where they conduct business and implement interoperable transaction systems to remain compliant under the November 2024 enforcement standard.

What ColdChainCheck Data Shows

Of 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, current compliance scores suggest uneven DSCSA readiness across the industry. The average score of 51/100 places the typical distributor in the "Fair" tier — indicating basic licensure and FDA registration but incomplete third-party validation signals.

The compliance score distribution reveals three readiness clusters:

High-readiness entities (309 distributors scoring 70+): These entities hold licenses in 25+ states, maintain NABP accreditation, and show clean enforcement records. This group represents 24% of the directory — likely the first-mover distributors who invested in interoperable systems during the DSCSA transition period.

Mid-readiness entities (919 distributors scoring 40-69): The majority cluster holds FDA registration and state licenses in 5-15 jurisdictions but lacks NABP accreditation. Multi-state operations in this tier face pressure to expand licensing coverage or risk geographic limitations under the new enforcement standard.

Low-readiness entities (47 distributors scoring below 40): This tail includes entities with expired licenses, limited state coverage, or enforcement actions on record. The 73 entities with FDA recalls represent a subset requiring enhanced due diligence — recalls signal potential gaps in quality systems that may extend to DSCSA compliance infrastructure.

NABP accreditation data highlights a structural gap. Only 63 entities (4.9% of the directory) hold current VAWD accreditation. As health systems increasingly mandate third-party validation, the 1,212 non-accredited distributors face competitive disadvantage — particularly in specialty pharmaceutical distribution where trading partner standards exceed baseline regulatory requirements.

Practical Steps for Compliance Officers

• Audit current trading partners: Use the ColdChainCheck directory to verify each distributor holds active licenses in relevant jurisdictions. Filter by state and check license status dates — expired or suspended licenses trigger immediate DSCSA compliance failures.

• Prioritize NABP-accredited sources: The 63 VAWD-accredited entities in the directory represent lower-risk trading partners. Cross-reference accreditation status against internal vendor lists to identify gaps in third-party validation coverage.

• Monitor enforcement signals: The 73 entities with FDA recalls on record warrant enhanced due diligence. Review recall dates, affected products, and corrective actions to assess whether quality system deficiencies may impact DSCSA data integrity.

• Document verification protocols: Maintain records of trading partner checks performed through ColdChainCheck or state board of pharmacy databases. FDA inspections under the November 2024 enforcement guidance will verify distributors maintain systematic verification processes, not ad hoc spot checks.

ColdChainCheck tracks state licensing, NABP accreditation, and FDA enforcement actions as core compliance signals. The compliance score methodology weights these inputs to provide a standardized readiness indicator. Additional DSCSA-specific guidance covering VRS integration and EPCIS data requirements is available in the compliance guides section.

Disclaimer: This article provides informational content based on publicly available regulatory guidance and ColdChainCheck directory data as of the publication date. It does not constitute legal or compliance advice. Verify all regulatory requirements with the FDA, relevant state boards of pharmacy, and qualified legal counsel.